Why Scholar Rock Stock Got Socked on Monday

Group 1 - Scholar Rock's share price fell over 13% due to a potential delay in an important submission, contrasting with a 1.6% gain in the S&P 500 [1] - The FDA has designated Scholar Rock's third-party manufacturing facility, Catalent Indiana, as Official Action Indicated (OAI), indicating recommended regulatory actions [2][3] - Catalent Indiana, owned by Novo Nordisk, serves as a third-party manufacturer for various biotech and pharmaceutical companies, including Scholar Rock and Regeneron [4] Group 2 - Scholar Rock faced a setback when the FDA rejected its biologics license application (BLA) for the apitegromab drug for spinal muscular atrophy (SMA) [5] - The company plans to continue collaboration with Novo Nordisk and will provide further updates during its third-quarter earnings call [6]